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Background. This analysis sought to determine the associations of the Foundation for the National Institutes of 
Health Sarcopenia Project criteria for weakness and low lean mass with likelihood for mobility impairment (gait speed  
≤ 0.8 m/s) and mortality. Providing validity for these criteria is essential for research and clinical evaluation.
Methods. Among 4,411 men and 1,869 women pooled from 6 cohort studies, 3-year likelihood for incident mobility impair-
ment and mortality over 10 years were determined for individuals with weakness, low lean mass, and for those having both. 
Weakness was defined as low grip strength (<26 kg men and <16 kg women) and low grip strength-to-body mass index (BMI; 
kg/m2) ratio (<1.00 men and <0.56 women). Low lean mass (dual-energy x-ray absorptiometry) was categorized as low appen-
dicular lean mass (ALM; <19.75 kg men and <15.02 kg women) and low ALM-to-BMI ratio (<0.789 men and <0.512 women).
Results. Low grip strength (men: odds ratio [OR] = 2.31, 95% confidence interval [CI] = 1.34–3.99; women: OR 
= 1.99, 95% CI 1.23–3.21), low grip strength-to-BMI ratio (men: OR = 3.28, 95% CI 1.92–5.59; women: OR = 2.54, 
95% CI 1.10–5.83) and low ALM-to-BMI ratio (men: OR = 1.58, 95% CI 1.12–2.25; women: OR = 1.81, 95% CI 
1.14–2.87), but not low ALM, were associated with increased likelihood for incident mobility impairment. Weakness 
increased likelihood of mobility impairment regardless of low lean mass. Mortality risk patterns were inconsistent.
Conclusions. These findings support our cut-points for low grip strength and low ALM-to-BMI ratio as candidate 
criteria for clinically relevant weakness and low lean mass. Further validation in other populations and for alternate 
relevant outcomes is needed.
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ROSENBERG (1) first highlighted the functional signifi-cance of the ubiquitous age-related loss of muscle mass 
by naming it “sarcopenia,” and a surge of investigations into 
the functional consequences of low lean mass soon followed 
(2,3). It has become clear, however, that low lean mass, by 
itself, is a poor predictor of functional outcomes compared 
with low strength (4,5). Operational definitions of sarcopenia 
have evolved to include measures of strength and function, 
and several recommendations for clinical criteria have been 
published (6–9), yet there are currently no data-driven con-
sensus criteria validated for their ability to predict relevant 
clinical outcomes. The Foundation for the National Institutes 
of Health (FNIH) Sarcopenia Project aimed to address this 
gap in knowledge, and in the first two phases of the project, 
we determined preliminary, evidence-based cut-points for 
both grip strength and grip strength standardized to body size 
as candidate indicators of clinically relevant weakness (10), 
and cut-points for both appendicular lean mass (ALM) and 
ALM standardized to body size as candidate criteria for clini-
cally relevant low lean mass (11). 
In the third phase, presented here, we sought to validate 
our candidate criteria by determining whether they predict 
future mobility impairment, defined as usual gait speed ≤0.8 
m/s (12), over a 3-year follow-up among those without cur-
rent mobility impairment. Testing this hypothesis is impor-
tant to provide further evidence about whether to adopt 
these proposed criteria for research and clinical evaluation. 
In supplemental analyses, we examined all-cause mortality 
as a secondary clinically relevant outcome.
Methods
Participants
Recruitment criteria and description of the studies par-
ticipating in the FNIH Sarcopenia Project have been pre-
viously described (10,11). Eligible participants for the 
current analyses included those from cohorts with concur-
rent information on gait speed, grip strength, and ALM at a 
single time point (baseline), baseline age ≥65 years, base-
line gait speed >0.8 m/s, a follow-up gait speed measure-
ment approximately 3 years after baseline, and follow-up 
information on survival. Of the 26,625 participants in the 
pooled data, 8,371 were ineligible because they were from 
studies without follow-up data; 10,052 did not have dual-
energy x-ray absorptiometry scans or follow-up data; 960 
were eligible but missing gait speed, grip strength, or ALM; 
and an additional 962 were missing follow-up data, yielding 
a final sample size of 6,280 (4,411 men and 1,869 women). 
Follow-up gait speed data were missing from 665 partici-
pants, leaving 5,615 (4,034 men and 1,581 women) eligible 
for analyses of incident mobility impairment. The final sam-
ple included participants from the Study of Osteoporotic 
Fractures original (study visit 6) (13) and African American 
cohorts (study visit 1; 14), the Osteoporotic Fractures in 
Men Study Sleep Study ancillary study (15–17), the Health, 
Aging and Body Composition study (year-6 clinic visit; 
18), the Framingham Study Offspring cohort (exam cycles 
6 and 7, 1996–2001; 19), and men from the Invecchiare in 
Chianti study (year-3 visit; 20). 
Grip Strength
Maximum grip strength (kilograms) was measured using a 
handheld dynamometer using similar protocols across studies. 
Most studies used a Jamar dynamometer (Sammons Preston 
Rolyan, Bolingbrook, IL; 21). Grip strength less than 26 kg for 
men and less than 16 kg for women was considered weak (10). 
A secondary criteria for weakness based on grip strength-to-
body mass index (BMI) ratio (weak
BMI
) was also determined, 
with weakness defined as weak
BMI
 less than 1.00 in men and 
less than 0.56 in women (10).
Lean Mass
Whole-body dual-energy x-ray absorptiometry scans were 
obtained with either a Lunar or Hologic densitometer using 
similar protocols across studies. Our low lean mass criteria 
was defined as ALM less than 19.75 kg for men and less than 
15.02 kg for women (11). A secondary criteria for low lean 
mass based on ALM-to-BMI ratio (ALM
BMI
) was identified, 
with low ALM
BMI
 defined as less than 0.789 in men and less 
than 0.512 in women (11).
Gait Speed
Gait speed (meters per second) was assessed at baseline 
and after approximately 3 years of follow-up as speed over a 
4-m course at the usual pace. For cohorts using a 6-m course, 
gait speed was converted to 4-m speeds using a published 
formula (22). Mobility impairment was defined as a gait 
speed ≤0.8 m/s (12).
Mortality
Date of death (any cause) for participants was ascer-
tained according to protocols for each cohort. Survival time 
was calculated as the number of days from the baseline visit 
until death or up to 10 years of follow-up.
Other Variables
Information on baseline age (years) and BMI (weight in 
kilograms divided by height in meters squared, kg/m2) was 
available in all participants.
Statistical Analyses
To evaluate potential differences between participants 
included and excluded from the mobility impairment anal-
ysis, we compared baseline characteristics between those 
who did and did not have follow-up mobility impairment 
information up using analysis of variance or the Kruskal–
Wallis test for continuous variables, and the chi-square test 
for categorical variables.
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We planned a priori to pool data across all cohorts to 
evaluate the predictive validity of our candidate criteria 
for incident mobility impairment and mortality. For both 
outcomes, we calculated cohort-specific effect estimates 
(SAS version 9.2, SAS Institute Inc. Cary, NC), which 
were then combined to calculate pooled effect estimates 
using random-effects meta-analysis (23) using the Metafor 
package for R.  The presence and extent of heterogeneity 
among studies were evaluated using the Q test (p < .10) and 
I2 statistic.
Logistic regression was used to calculate the age-
adjusted odds ratios (ORs) and 95% confidence intervals 
(CIs) for incident mobility impairment for our weak-
ness (weak and weak
BMI
) and low lean mass (ALM and 
ALM
BMI
) criteria, separately for men and women. To 
determine whether combinations of weakness and low 
lean mass criteria predict incident mobility impairment, 
participants were further categorized into four groups: (a) 
not weak with normal lean mass, (b) not weak with low 
lean mass, (c) weak with normal lean mass, and (d) weak 
with low lean mass. ORs for incident mobility impairment 
were calculated for each group with the “not weak with 
normal lean mass” group as the referent. Analysis was 
done separately for each of the four different combina-
tions of our weakness and low lean mass criteria: (a) weak 










For mortality, we used Cox proportional hazards regres-
sion to calculate the sex-specific age-adjusted mortality rate 
ratios and 95% CIs for the weakness and low lean mass 
criteria, and for their combinations. No violations of the 
proportional hazards assumption were detected (p < .05 for 
interactions of independent variables with time). 
Results
Among the 6,280 participants eligible for mobility 
impairment and mortality analyses, more women had 
low ALM compared to men (38% vs 9%), but the preva-
lence of low ALM
BMI
 (15% vs 18%) was similar (Table 1). 
Weakness defined by weak and weak
BMI
 was prevalent 
in 3% and 6% of men, respectively, and 11% of women 
for both definitions. The proportion of men and women 
with combined weakness and low lean mass was very low 
(≤7%) regardless of definition used. Baseline character-
istics by participating cohort are listed in Supplementary 
Tables 1 and 2.
Incident Mobility Impairment
The 377 men (8.5%) excluded from the incident mobil-
ity impairment analysis due to missing follow-up mobility 
data were older, slower, weaker, and had lower BMI and 
lean mass than men who were included (Supplementary 
Table  3). The 288 (15%) excluded women were older, 
slower, and had lower lean mass. For the 5,615 participants 
included, 7% of men and 23% of women developed inci-
dent mobility impairment (Supplementary Table 4).
Weak (Figure 1) was associated with a twofold higher 
odds of mobility impairment for men (OR = 2.31, 95% CI 
1.34–3.99) and women (OR = 1.99, 95% CI 1.23–3.21). 
Weak
BMI
 (Figure 2) was more strongly associated with inci-
dent mobility impairment in both men (OR = 3.28, 95% CI 
1.92–5.59) and women (OR = 2.54, 95% CI 1.10–5.83), 
though there was evidence of heterogeneity among women 
(Q test: p < .01; I2 = 80%).
Low lean mass defined by ALM
BMI
 (Figure 3) was associ-
ated with higher odds of incident mobility impairment for both 
Table 1. Baseline Characteristics* of FNIH Sarcopenia Project 
Participants Included in Longitudinal Analyses Including Pre-
specified Categorizations of Baseline Weakness and Low Lean Mass 
Women Men
N 1,869 4,411
Age (y) 76.5 ± 4.5 74.0 ± 5.5
BMI (kg/m2) 27.3 ± 5.1 27.3 ± 3.7
 <25 (%) 34 27
 25 to <30 (%) 38 53
 ≥30 (%) 26 20
Gait speed (m/s) 1.1 ± 0.2 1.3 ± 0.2
Grip strength (kg) 22.1 ± 5.8 41.3 ± 8.5
Grip strength/BMI 0.83 ± 0.24 1.54 ± 0.36
ALM (kg) 16.2 ± 2.9 24.1 ± 3.4
ALM/BMI 0.60 ± 0.09 0.89 ± 0.11
Weak† (%) 11 3
Weak
BMI
‡ (%) 11 6
Low ALM§ (%) 38 9
Low ALM
BMI
|| (%) 15 18
Weak + ALM
 Not weak, normal lean mass (%) 58 89
 Not weak, low lean mass (%) 31 8
 Weak, normal lean mass (%) 4 2
 Weak, low lean mass (%) 7 1
Weak + ALM
BMI
 Not weak, normal lean mass (%) 77 81
 Not weak, low lean mass (%) 12 17
 Weak, normal lean mass (%) 9 1




 Not weak, normal lean mass (%) 55 86
 Not weak, low lean mass (%) 34 8
 Weak, normal lean mass (%) 7 5





 Not weak, normal lean mass (%) 79 80
 Not weak, low lean mass (%) 10 14
 Weak, normal lean mass (%) 7 2
 Weak, low lean mass (%) 4 4
Died over follow-up (%) 18 19
Mean follow-up time (y) 7.4 8.4
Notes: ALM = appendicular lean mass; BMI = body mass index.
*Mean (±SD) unless otherwise noted.
†Weak: grip strength <26 men; <16 women.
‡Weak
BMI
: ratio of grip strength-to-body mass index <1.00 men; <0.56 women.
§ALM: appendicular lean mass <19.75 men; <15.02 women.
||ALM
BMI
: ratio of appendicular lean mass to body mass index <0.789 men; 
<0.512 women. 
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men (OR = 1.58, 95% CI = 1.12–2.22) and women (OR = 1.81, 
95% CI 1.14–2.87), yet the ALM criterion was not (Figure 4).
Men who were weak with normal lean mass had two 
to nearly five times the odds of incident mobility impair-
ment than those who were not weak with normal lean mass 
(Supplementary Figures 1–4). This group also tended to have 
greater odds of mobility impairment than weak men with 
low lean mass, with the exception of the weak + ALM
BMI
 
combination (Supplementary Figure  2), where weak men 
with low lean mass had the greatest odds of mobility impair-
ment, though there was some evidence of heterogeneity 
across cohorts for the not weak with low lean mass group 
(Q test: p = .08, I2 = 51%). Among men who were not weak, 
low lean mass defined by either criterion was not associ-
ated with incident mobility impairment. When weakness 
and low lean mass criteria were combined in women, there 
was significant heterogeneity among cohorts for the com-
binations of weak +ALM, weak
BMI 





 (Q test: all p < .10, all I2 > 52%). For the weak + 
ALM
BMI
 combination (Supplementary Figure 2), there were 
higher odds in all three risk groups relative to the not weak 
with “normal lean mass group,” with the highest odds in the 
“weak with low lean mass” group.
Mortality
Over 10  years of follow-up, 18% of women and 19% 
of men died (Supplementary Table 1). Weak and weak
BMI
 
criteria were associated with 63%–74% higher mortal-
ity rates among men, whereas in women, only weak was 
associated with a 48% higher rate (Supplementary Figures 
5–6). Among men, ALM was associated with 37% greater 
morality rate, while ALM
BMI
 was not associated with mor-
tality (Supplementary Figures 7–8), though there was sig-
nificant heterogeneity for this criterion (Q test: p = .02, I2 
= 75%). Neither ALM nor ALM
BMI
 were associated with 
mortality among women. For all combinations of weak-
ness and low lean mass criteria among men, mortality rates 
were consistently highest among those with weakness, 
though estimates were statistically significant only for men 
with normal lean mass (Supplementary Figures 9–12). 
Among men who were not weak, ALM was associated 
with 33%–41% higher mortality rate compared to normal 
lean mass, yet there was evidence of significant heteroge-
neity for ALM
BMI
. For combinations of weakness and low 
lean mass among women, those who were weak tended 
to have increased mortality rates, though mortality rate 
ratio CIs exclude the null value only for those who were 
Figure 1. Age-adjusted odds ratios (OR) for incident mobility impairment (gait speed ≤ 0.8 m/s) after approximately 3 years of follow-up for proposed low grip 
strength criteria (weak) among men (A) and women (B) in the FNIH Sarcopenia Project.
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weak with low lean mass for the weak + ALM combina-
tion (Supplementary Figure 9), and those who were weak 
with normal lean mass for the weak + ALM
BMI
 combina-
tion (Supplementary Figures 10).
Discussion
Our results suggest that our criteria for low-absolute grip 
strength (weak) and low BMI-standardized grip strength 
(weak
BMI
) both strongly predict incident mobility impair-
ment after 3 years among nonimpaired older men and 
women, although in women there was evidence of hetero-
geneity among cohorts for the association with weak
BMI
. 
Low BMI-standardized ALM (ALM
BMI
) was not as strongly 
associated with incident mobility as weakness, but it did 
significantly predict incident mobility impairment. When 
we explored whether the likelihood for mobility impair-
ment varied across groups defined by combinations of our 
weakness and low lean mass criteria, there was no clear 
performance difference among the different combinations 
among the men. Yet among women, the weak + ALM
BMI
 
combination was the only one for which there was no evi-
dence of heterogeneity among cohorts in the women. Based 
on our overall findings, we recommend weak and ALM
BMI
 
as potential criteria for clinically relevant weakness and low 
lean mass, respectively, among older men and women.
Those classified as weak had significantly greater odds 
of mobility impairment compared to those who were not 
weak, yet among the weak, the odds were similar for those 
with and without low lean mass. This finding suggests that 
among those without mobility problems, weakness is likely 
the key to identifying individuals at risk for future mobility 
impairment. Our results are consistent with the literature in 
that muscle strength is a stronger predictor of mobility prob-
lems than lean mass (5,24,25). The observed higher risk for 
mobility impairment in the group that was weak but had nor-
mal lean mass also highlights the important contributions 
of nonmass factors for muscle function, such as inter- and 
intramuscular fat infiltration (26,27), excitation-contraction 
coupling (28), and functions of the central nervous system 
and neuromuscular junction (29). Yet while weakness is 
clearly clinically important, there may be a specific subgroup 
among the weak for whom low muscle mass is an important 
cause of their weakness. It is important for clinicians to be 
able to identify these patients because they are the most likely 
to benefit from therapies that increase muscle mass. Our cut-
points may be useful for finding these individuals who are 
Figure 2. Age-adjusted odds ratios (OR) for incident mobility impairment (gait speed ≤ 0.8 m/s) after approximately 3 years of follow-up for proposed low grip 
strength-to-BMI ratio criteria (weak
BMI
) among men (A) and women (B) in the FNIH Sarcopenia Project.
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both weak and have low lean mass. The low numbers of indi-
viduals who were classified as having both weakness and low 
lean mass in our analyses (≤8% of women and ≤4% of men), 
was due, in part, to the fact that our studies were composed of 
generally healthy, nondisabled older adults. Future research 
is needed to determine whether improvements in lean mass 
among those who are weak translate into improved mobility.
Two recent prospective studies evaluated the validity of the 
European Working Group on Sarcopenia in Older People sar-
copenia criteria (7) for predicting mortality in older adults: 
Arango-Lopera and colleagues (30) examined 345 residents 
of Mexico City, who were aged 70 years or older, over 3 years 
of follow-up, and Landi and colleagues (31) followed 364 
men and women, who were aged 80–85 years and living in 
the Sirente area of Italy, for 7 years. In both cohorts, sarcope-
nia, defined by the European Working Group on Sarcopenia 
in Older People as slow gait speed or low grip strength com-
bined with low lean mass, was associated with a greater 
than twofold higher risk for all-cause mortality. Because the 
European Working Group on Sarcopenia in Older People 
criteria combines both weakness and low lean mass in a sin-
gle classification of sarcopenia, these prior studies could not 
determine which of these two elements may be most impor-
tant for predicting mortality. Similar to incident mobility 
impairment, our all-cause mortality results support weakness 
over low lean mass as the predominant predictor of clinical 
outcomes. Both of our weakness criteria predicted mortality 
among men, although in women only weakness by absolute 
grip strength was associated with mortality. Conversely, low 
lean mass was not a consistent predictor of mortality in either 
men or women. Combining weakness and low lean mass cri-
teria resulted in no consistent patterns of associations for the 
four groups, though results suggested that those classified as 
weak had the highest mortality rates regardless of their lean 
mass status. Our mortality results were not fully consistent 
with the mobility impairment results perhaps because death is 
farther down the causal pathway from strength and lean mass 
than mobility impairment. Additional studies are needed to 
examine the relation of our criteria with other, more proximal 
relevant clinical geriatric outcomes (eg, self-reported disabil-
ity, active vs disabled life expectancy, falls).
This study has some important limitations. First, mobil-
ity impairment analyses included only those who were not 
impaired at baseline. Thus, further investigation of the ability 
of our criteria to predict relevant clinical outcomes within more 
impaired populations is needed. Nevertheless, our criteria may 
identify subgroups of older adults that may be targeted for pre-
vention of mobility problems. Second, results may have been 
influenced by differences among the pooled cohorts, includ-
ing the varying follow-up times for gait speed assessments. 
Figure 3. Age-adjusted odds ratios (OR) for incident mobility impairment (gait speed ≤ 0.8 m/s) after approximately 3 years of follow-up for proposed low 
appendicular lean mass criteria (ALM) among men (A) and women (B) in the FNIH Sarcopenia Project.
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In our meta-analyses, however, we did assess the heterogene-
ity across cohorts for associations of weakness and low lean 
mass criteria with mobility impairment and mortality, and we 
selected our recommended criteria only from among those 
without statistically significant evidence for heterogeneity. 
Third, over 26,000 individuals were included in the Sarcopenia 
Project, yet only 6,280 were included in the current analysis, 
limiting generalizability. Fourth, it is important to note that 
there are many other factors apart from muscle strength and 
mass that contribute to incident mobility impairment in older 
adults, which we did not account for in our analyses. In partic-
ular, several co-morbid conditions can influence the amount of 
strength required to ambulate (32). Nevertheless, in this initial 
phase of the Sarcopenia Project, our goal was to establish the 
predictive validity of our criteria for the general population of 
community-dwelling older adults. Future work should assess 
the performance of these preliminary criteria within relevant 
disease states as well as other specific populations (eg, insti-
tutionalized older adults, racial/ethnic groups). Finally, the 
methods used to derive our cut-points for weakness and low 
lean mass do not provide estimates of precision nor do they 
evaluate any underlying biologic relation among strength, lean 
mass, and mobility (10,11). Thus, our proposed criteria should 
be interpreted as preliminary recommendations.
Our study has several strengths. This is the largest 
endeavor to date to develop data-driven criteria for clini-
cally relevant weakness and low lean mass. Our analy-
ses included a large number of men and women from six 
diverse, community-based cohorts with information on 
objective measures of lean mass, strength, and mobility, 
as well as longitudinal information on incident mobility 
impairment and mortality, two clinically important aging 
outcomes. We analyzed pooled, individual-level data, which 
has advantages over aggregating results from individual 
studies, including assessment of individual-level missing 
data, standardized statistical analysis, and consistent adjust-
ment for confounders (33).
Conclusion
Among older adults without mobility impairment, our 
criteria for clinically relevant weakness and low lean mass 
predict incident mobility impairment over 3 years of fol-
low-up. Our analyses suggest that grip strength (<26 kg in 
men and <16 kg in women) and ALM standardized to BMI 
(<0.789 in men and <0.512 in women) are preliminary can-
didate criteria for weakness and low lean mass, respectively. 
These cut-points must be evaluated in additional studies to 
Figure 4. Age-adjusted odds ratios (OR) for incident mobility impairment (gait speed ≤ 0.8 m/s) after approximately 3 years of follow-up for proposed low 
appendicular lean mass-to-BMI ratio criteria (ALM
BMI
) among men (A) and women (B) in the FNIH Sarcopenia Project.
 WEAKNESS, LOW LEAN MASS, AND MOBILITY 583
determine whether they identify the groups of older adults 
with mobility problems that are likely to benefit from inter-
ventions designed to maintain or improve mobility.
Supplementary Material 
Supplementary material can be found at: http://biomedgerontology.
oxfordjournals.org/
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